公开(公告)号：US12128099B2

公开(公告)日：2024-10-29

申请号：US17058765

申请日：2019-05-24

Applicant: BIOVENTURES, LLC

Inventor： Jia Liu ,  Martin Cannon

IPC: A61K35/00 ,  A61K39/00 ,  A61K39/275 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/275 ,  A61K39/0011 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/585 ,  A61K2039/892

Abstract: Mutant Myxoma viruses are provided herein and methods of using these viruses to treat cancer or elicit an interferon response in a subject are also provided. The mutant Myxoma virus is modified to reduce or eliminate the activity or expression of Myxoma virus protein M62 as compared to a control virus. The mutant virus is capable of stimulating an interferon response in subjects after administration and can also lead to inhibition, reduction or elimination of the CD14+ tumor associated macrophage inhibition of CD4+ T cells in a subject having cancer and lead to a change in the tumor microenvironment to treat the cancer or work in combination with other cancer therapeutics to treat the cancer as described herein.

公开(公告)号：US20240342266A1

公开(公告)日：2024-10-17

申请号：US18755746

申请日：2024-06-27

Applicant: GUANGZHOU ANJIE BIOMEDICAL TECHNOLOGY CO., LTD.

Inventor： Chao Zhou ,  Hong An ,  Ling Zhou ,  Yongbiao Du ,  Pengyun Liao ,  Taoxi Wang ,  Haibin Michael Yin

IPC: A61K39/12 ,  A61K39/00 ,  A61K41/00 ,  A61P35/00 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K39/12 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464838 ,  A61K41/0047 ,  A61P35/00 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/585 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12N2710/10051 ,  C12N2740/15043

Abstract: The present application belongs to the technical field of gene therapy, and discloses a method for treating a tumor with a combination of an exogenous antigen and a therapeutic agent. The present application also discloses a composition including an exogenous antigen and a therapeutically effective amount of a therapeutic agent. With the exogenous antigen as a target, the therapeutic agent kills a tissue or cell carrying the exogenous antigen and does not act on any tissue or cell without the exogenous antigen, thereby specifically killing the tissue or cell, such as a tumor cell. Since the exogenous antigen can be expressed in different types of tumors in different individuals, the method of the present application is a broad-spectrum anti-tumor method.

公开(公告)号：US20240327921A1

公开(公告)日：2024-10-03

申请号：US18129791

申请日：2023-03-31

Applicant: Cameron Kamran Tebbi

Inventor： Cameron Kamran Tebbi

IPC: C12Q1/6886 ,  A61K39/00

CPC classification number: C12Q1/6886 ,  A61K39/0002 ,  A61K2039/585 ,  A61K2039/804 ,  C12Q2600/156

Abstract: A method for detection and prevention of leukemia and lymphoma is disclosed. When mononuclear blood cells from an individual are exposed to a supernatant of a mycovirus-containing Aspergillus flavus, the degree and pattern of activation and upregulation or downregulation transcription factors are indicative of an individual's susceptibility to leukemia or lymphoma. Upon detection of observed transcription factors, preventive measures are provided to the individual. Preventive measures may include, for example, a vaccine, or may be provided upon detection of observed transcription factors with those individuals that are genetically susceptible to leukemia and lymphoma.

公开(公告)号：US20240299518A1

公开(公告)日：2024-09-12

申请号：US18663847

申请日：2024-05-14

Applicant: CENTRO DE INMUNOLOGIA MOLECULAR

Inventor： BELINDA SÁNCHEZ RAMÍREZ ,  GRETCHEN BÁEZ BERGADO ,  NARJARA GONZÁLEZ SUÁREZ ,  MABEL CRUZ RODRÍGUEZ ,  DIANA ROSA HERNÁNDEZ FERNÁNDEZ ,  LISSET CHAO GARCÍA

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/001106 ,  A61K39/001104 ,  A61P35/00 ,  A61K2039/55555 ,  A61K2039/585 ,  A61K2039/70 ,  A61K2039/82 ,  A61K2039/852

Abstract: The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.

公开(公告)号：US20240299517A1

公开(公告)日：2024-09-12

申请号：US18671331

申请日：2024-05-22

Applicant: University of Maryland, Baltimore

Inventor： Eduardo DAVILA ,  Koji TAMADA

IPC: A61K39/00 ,  A61K35/17 ,  A61K39/395 ,  A61K47/54 ,  A61K47/68 ,  C07K16/28 ,  C07K16/44 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K39/39558 ,  A61K47/555 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6897 ,  C07K16/2863 ,  C07K16/44 ,  C12N5/0636 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/622 ,  C07K2319/00 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

公开(公告)号：US20240299516A1

公开(公告)日：2024-09-12

申请号：US18268725

申请日：2021-12-20

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATON, INC.

Inventor： Elias Sayour ,  Hector Ruben Mendez-Gomez ,  Duane A. Mitchell

IPC: A61K39/00 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K9/1272 ,  A61P35/00 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/585

Abstract: The disclosure provides a method of treating cancer in a human subject. The method comprises, e.g., administering a dose of nanoparticles every two weeks for an initial treatment period, then administering a dose of nanoparticles once a month for a subsequent treatment period. The nanoparticles comprise a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, each nucleic acid layer being positioned between a cationic lipid bilayer, wherein the nucleic acids are derived from a cancer cell. The dose comprises about 0.00050 mg/kg to about 1.5 mg/kg of nucleic acid.

公开(公告)号：US20240285792A1

公开(公告)日：2024-08-29

申请号：US18426706

申请日：2024-01-30

Applicant: CASE WESTERN RESERVE UNIVERSITY ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： Nicole F. Steinmetz ,  Stephen Lippard ,  Anna Czapar ,  Yaorong Zheng

IPC: A61K47/69 ,  A61K9/00 ,  A61K9/51 ,  A61K31/555 ,  A61K39/00 ,  A61K39/12 ,  A61P35/00

CPC classification number: A61K47/6901 ,  A61K9/0019 ,  A61K9/5184 ,  A61K31/555 ,  A61K39/12 ,  A61P35/00 ,  A61K2039/585 ,  C12N2750/12022 ,  C12N2750/12023 ,  C12N2770/00034 ,  C12N2770/00042 ,  C12N2770/32022 ,  C12N2770/32023

Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.

公开(公告)号：US20240269271A1

公开(公告)日：2024-08-15

申请号：US18407567

申请日：2024-01-09

Applicant: VIRION THERAPEUTICS, LLC ,  THE WISTAR INSTITUTE

Inventor： Hildegund CJ Ertl ,  Sue L. Currie ,  Andrew D. Luber

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K14/47

CPC classification number: A61K39/39 ,  A61K39/12 ,  C07K14/005 ,  C07K14/47 ,  A61K2039/5256 ,  A61K2039/55516 ,  A61K2039/585 ,  C07K2319/00 ,  C12N2710/20022 ,  C12N2710/20034

Abstract: Disclosed herein are compositions for increasing the immunogenicity of a vaccine antigen and methods of inducing an immune response in a subject using the compositions described herein. Disclosed herein are compositions for a therapeutic vaccine to HPV-associated cancers and methods of inducing an immune response to HPV in a subject using the compositions described herein.

公开(公告)号：US20240261382A1

公开(公告)日：2024-08-08

申请号：US18567058

申请日：2022-06-06

Applicant: INNOBM PHARMACEUTICALS CO., LTD.

Inventor： Zhuang LIU ,  Rui PENG ,  Chenya WANG ,  Qi ZHUANG ,  Qi ZHAO

IPC: A61K39/112 ,  A61K39/00 ,  A61K39/085 ,  A61K39/09 ,  A61K39/108 ,  A61P35/00 ,  C12N1/20

CPC classification number: A61K39/0275 ,  A61K39/0258 ,  A61K39/085 ,  A61K39/09 ,  A61P35/00 ,  C12N1/20 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/585

Abstract: A modified bacterium, a preparation method thereof and an application thereof. The modified bacterium comprises a bacterium body and a poorly soluble or insoluble biologically acceptable metal compound modified on the surface of the bacterium body. After the modified bacterium is injected in a tumor, an anti-tumor immune response can be activated, an excellent anti-tumor treatment is activated, and tumor metastasis and recurrence can be effectively inhibited.

公开(公告)号：US20240252611A1

公开(公告)日：2024-08-01

申请号：US18385250

申请日：2023-10-30

Applicant: ABALOS THERAPEUTICS GMBH

Inventor： Karl Sebastian Lang ,  Halime Kalkavan

IPC: A61K39/12 ,  A61K35/76 ,  A61K35/768 ,  A61K39/00 ,  A61P35/00 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K35/76 ,  A61K35/768 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/585 ,  A61P35/00 ,  C12N2760/10011 ,  C12N2760/10021 ,  C12N2760/10032 ,  C12N2760/10033

Abstract: The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and also a method for preparing arenaviruses with (improved) tumor-regressive properties.